Response to Crizotinib Re-administration After Progression on Lorlatinib in a Patient With ALK-rearranged Non–small-cell Lung Cancer

Clinical Practice Points•Non–small-cell lung cancer (NSCLC) with anaplastic lymphoma kinase (ALK) gene rearrangement is sensitive to ALK-tyrosine kinase inhibitors (TKIs). First- and second-generation ALK-TKIs are effective for ALK-rearranged NSCLC; however, resistance to ALK-TKI treatment arises.•Lorlatinib is a third-generation ALK-TKI and shows clinical activity for patients who have undergone previous ALK-TKI treatment. Although the response...